Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Trial Details

NCT ID

NCT05868395

Phase

PHASE2

Sponsor

Medical University of Vienna

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Polatuzumab, bendamustin und rituximab

Locations (sample)

• Vienna, Austria|48.20849,16.37208

Key Eligibility Criteria

• Capability of understanding the purpose of the study and have given written informed consent.
• Age greater than or equal to 18 years
• Histologically or cytologically confirmed relapsed or refractory MCL
• r/r MCL patients following standard first line chemotherapy who have received at least one prior regimen including ibrutinib

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.